97 related articles for article (PubMed ID: 27268602)
1. Significance of Some Proliferation Markers and Some Prognostic Factors in Patients with Multiple Myeloma and their Impact on the Patients' Survival.
Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
Asian Pac J Cancer Prev; 2016; 17(5):2389-94. PubMed ID: 27268602
[TBL] [Abstract][Full Text] [Related]
2. Significance of Proliferation Markers and Prognostic Factors in Egyptian Patients with Multiple Myeloma.
Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
Asian Pac J Cancer Prev; 2016; 17(3):1351-5. PubMed ID: 27039771
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.
Lemancewicz D; Bolkun L; Jablonska E; Kulczynska A; Bolkun-Skornicka U; Kloczko J; Dzieciol J
Leuk Res; 2013 Sep; 37(9):1089-93. PubMed ID: 23768867
[TBL] [Abstract][Full Text] [Related]
4. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.
Fragioudaki M; Tsirakis G; Pappa CA; Aristeidou I; Tsioutis C; Alegakis A; Kyriakou DS; Stathopoulos EN; Alexandrakis MG
Leuk Res; 2012 Aug; 36(8):1004-8. PubMed ID: 22498341
[TBL] [Abstract][Full Text] [Related]
5. Cytokine profile in multiple myeloma.
Jasrotia S; Gupta R; Sharma A; Halder A; Kumar L
Cytokine; 2020 Dec; 136():155271. PubMed ID: 32916474
[TBL] [Abstract][Full Text] [Related]
6. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma.
Alexandrakis MG; Roussou P; Pappa CA; Messaritakis I; Xekalou A; Goulidaki N; Boula A; Tsirakis G
Biomed Res Int; 2013; 2013():389579. PubMed ID: 23936794
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma.
Alexandrakis MG; Goulidaki N; Pappa CA; Boula A; Psarakis F; Neonakis I; Tsirakis G
Pathol Oncol Res; 2015 Sep; 21(4):929-34. PubMed ID: 25743259
[TBL] [Abstract][Full Text] [Related]
8. B cell-activating factor: its clinical significance in multiple myeloma patients.
Fragioudaki M; Boula A; Tsirakis G; Psarakis F; Spanoudakis M; Papadakis IS; Pappa CA; Alexandrakis MG
Ann Hematol; 2012 Sep; 91(9):1413-8. PubMed ID: 22526370
[TBL] [Abstract][Full Text] [Related]
9. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
[TBL] [Abstract][Full Text] [Related]
10. Saliva and serum levels of B-cell activating factors and tumor necrosis factor-α in patients with periodontitis.
Gümüş P; Nizam N; Lappin DF; Buduneli N
J Periodontol; 2014 Feb; 85(2):270-80. PubMed ID: 23701482
[TBL] [Abstract][Full Text] [Related]
11. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
12. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of ligands belonging to tumour necrosis factor superfamily in acute lymphoblastic leukaemia.
Bolkun L; Lemancewicz D; Jablonska E; Szumowska A; Bolkun-Skornicka U; Moniuszko M; Dzieciol J; Kloczko J
Leuk Res; 2015 Mar; 39(3):290-5. PubMed ID: 25582383
[TBL] [Abstract][Full Text] [Related]
14. [BAFF level in bone marrow and expression of BAFF receptor on B cells in multiple myeloma patients].
Zhou ZH; Zhang L; Pan QY; Huang BH; Zheng D; Liu JR; Li J; Luo SK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1131-4. PubMed ID: 23114133
[TBL] [Abstract][Full Text] [Related]
15. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.
Mehtap O; Atesoglu EB; Tarkun P; Hacihanefioglu A; Dolasik I; Musul MM
J Postgrad Med; 2014; 60(2):141-4. PubMed ID: 24823512
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma].
Wang SM; Zhang TL; Jiang YM; Wu HY; Hao LM; Xing XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):395-8. PubMed ID: 21518495
[TBL] [Abstract][Full Text] [Related]
17. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
18. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y; Luetkens T; Kobold S; Hildebrandt Y; Gordic M; Lajmi N; Meyer S; Bartels K; Zander AR; Bokemeyer C; Kröger N; Atanackovic D
Exp Hematol; 2010 Oct; 38(10):860-7. PubMed ID: 20619313
[TBL] [Abstract][Full Text] [Related]
19. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
Hengeveld PJ; Kersten MJ
Blood Cancer J; 2015 Feb; 5(2):e282. PubMed ID: 25723853
[TBL] [Abstract][Full Text] [Related]
20. High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma.
Li YJ; Li ZM; Xia ZJ; Li S; Xia Y; Huang HQ; Huang JJ; Yi PY; Jiang WQ
Ann Hematol; 2015 Jan; 94(1):79-88. PubMed ID: 25146008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
